Apogee details its $10.9B AbbVie buyout, the UK launches a drug-pricing pilot, and Brii shares Phase 2b HBV vaccine data.
July 6, 2026 10:46 AM EDT
News Briefing
Apogee details path to $10.9B AbbVie deal; UK starts drug pricing pilot
Plus news about Brii Biosciences.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
AbbVie is buying Apogee Therapeutics, the developer of an experimental atopic dermatitis drug, for nearly $11B, continuing a run…
AbbVie strikes a $10.9B deal for Apogee, adding a long-acting IL-13 drug to its Humira-Skyrizi-Rinvoq I&I franchise.
In this week’s edition of InnovationRx, we look at AbbVie’s new megadeal, an agentic AI startup saving Medicare $2 million a…
AbbVie will acquire Apogee Therapeutics for $10.9 billion, with analyst citing long-term immunology growth despite near-term…
AbbVie will acquire Apogee for $10.9 billion, adding late-stage immunology and asthma assets to its pipeline.
Seg�n los t�rminos de un potencial acuerdo que est� en fase avanzada y que podr�a anunciarse el lunes, AbbVie pagar� un prima…
